reviewDrug Metabolism ReviewsFeb 15, 2017GREEN OA

Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters

University of Rhode Island

Indexed incrossref

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD. The pathological progression of NAFLD follows tentatively a “three-hit” process namely steatosis, lipotoxicity and inflammation. The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD. These factors may result in altered expression and activity of…

Citation impact

650
total citations
FWCI
20.50
Percentile
100%
References
171
Citations per year

Authors

2

Topics & keywords

Keywords
  • Fatty liver
  • Pathogenesis
  • Drug
  • Drug metabolism
  • Transporter
  • Enzyme
  • Disease
  • Alcoholic liver disease
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding